Alzheimer DiseaseTAMANCT02811653
Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
A study testing Brain MRI, neuropsychological evaluation and Blood in people with Alzheimer Disease, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized. Read more about this study
- Who is it for?
- Ages 40 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Alzheimer Disease
- What is being tested?
- Brain MRI, neuropsychological evaluation and Blood
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 155 participants
- Where
- 1 siteFrance
- Study dates
- 16 Dec 2015to 16 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients
- Age between 40 and 85
- French mother tongue
- Consulting at the Amiens Memory Resource and Research Centre (CMRR) for:
- MCI, according to Albert et al.'s criteria (Albert et al., 2011)
- Mild dementia (MMSE>20) due to AD, according to McKhann's criteria (McKhann et al., 2011).
Show all 11Show fewer
- Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005).
- Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011).
- Social security coverage
- Healthy controls
- Healthy age and gender matched volunteers will be recruited into the study from the general population.
Who cannot join
- Reading or writing difficulties related to a learning disorder or illiteracy.
- A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure):
- NYHA stage IV dyspnoea.
- respiratory impairment requiring oxygen therapy.
- liver impairment.
- kidney failure, progressing neoplastic disease, or past or present alcohol abuse.
Show all 24Show fewer
- Past or present neurological disorders other than those having prompted consultation in the Memory Clinic:
- stroke.
- meningitis or encephalitis.
- severe head injury.
- sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments).
- epilepsy (requiring ongoing treatment),
- psychiatric disorders (other than treated depression).
- treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state.
- Impossibility to perform a neuropsychological evaluation or brain MRI.
- Withdrawal from the study at any time, if desired.
- Pregnancy
- Contra-indication to MRI:
- nerve stimulators
- cochlear implants
- ferromagnetic foreign bodies close to nervous structures in the eye or brain
- cerebral shunts
- dental appliances
- Legal guardianship or incarceration.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Amiens
Amiens, 80054
Daniela ANDRIUTA, PhD, +33 3 22 66 82 40, andriuta.daniela@chu-amiens.fr
About this study
In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.
- Conditions
- Alzheimer Disease
- Being tested
- Brain MRI, neuropsychological evaluation, Blood
- Keywords
- Motor slowing
- Medical subject headings
- Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Brain MRIDevice
neuropsychological evaluationOther
BloodBiological
| Study group | Role | What they receive |
|---|---|---|
| Alzheimer disease | Experimental | Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation Receives: Device: Brain MRI; Other: neuropsychological evaluation; Biological: Blood |
| control | Active comparator | Healthy age- and gender-matched volunteers will be recruited into the study from the general population.
Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation Receives: Device: Brain MRI; Other: neuropsychological evaluation; Biological: Blood |
What is being measured
The primary outcome is the main question the study is designed to answer.
median SRT (simple reaction time) to a stimulus (in milliseconds)
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2016 (estimated)
- Study start16 Dec 2015
- Primary completion16 Dec 2028 (estimated)
- Study completion16 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire, AmiensThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 155 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Daniela ANDRIUTA, PhD, Principal investigator, CHU Amiens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02811653
- Sponsor's protocol ID
- PI2015_843_0003
- Acronym
- TAMA
- Status last verified
- May 2026
- First submitted
- 16 Jun 2016
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease
- ClinicalTrials.gov ID
- NCT02811653
- Acronym / sponsor ID
- TAMA / PI2015_843_0003
- Conditions
- Alzheimer Disease
- Keywords
- Motor slowing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 155 participants (estimated)
- Lead sponsor
- Centre Hospitalier Universitaire, AmiensUniversity, hospital or other
- Study start
- 16 Dec 2015 (actual)
- Primary completion
- 16 Dec 2028 (estimated)
- Study completion
- 16 Dec 2028 (estimated)
- First posted
- 23 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Alzheimer disease | Experimental | Device: Brain MRI, Other: neuropsychological evaluation, Biological: BloodAlzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation |
| control | Active comparator | Device: Brain MRI, Other: neuropsychological evaluation, Biological: BloodHealthy age- and gender-matched volunteers will be recruited into the study from the general population. Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation |
Who may qualify
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Patients
- Healthy controls
Key exclusion criteria (24 listed)
- Reading or writing difficulties related to a learning disorder or illiteracy.
- A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure):
- Past or present neurological disorders other than those having prompted consultation in the Memory Clinic:
- Impossibility to perform a neuropsychological evaluation or brain MRI.
- Withdrawal from the study at any time, if desired.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Brain MRI | Device | Alzheimer disease, control |
| neuropsychological evaluation | Other | Alzheimer disease, control |
| Blood | Biological | Alzheimer disease, control |
Primary outcome
median SRT (simple reaction time) to a stimulus (in milliseconds)
Time frame: Day 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
Related trials for Alzheimer Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
RecruitingPhase 3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Daniela ANDRIUTA, PhD principal investigator
CHU Amiens
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Brain MRI, neuropsychological evaluation and Blood in people with Alzheimer Disease, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Daniela ANDRIUTA, PhD (+33 3 22 66 82 40, andriuta.daniela@chu-amiens.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
median SRT (simple reaction time) to a stimulus (in milliseconds) (time frame: Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.